Latest News

STAT Plus: Launching a new gene therapy will be the biggest test yet for Novartis CEO Narasimhan




At the start of his second year on the job, Novartis CEO Vas Narasimhan is about to face his biggest test yet: the launch of a breakthrough gene therapy on which he spent $8.7 billion of his company’s cash last April.

Narasimhan, at 42 the youngest chief executive of a major pharmaceutical firm, spent his first year in command (he took over last February) talking about big goals — he wants to upgrade the company’s culture, turning the still-staid Swiss company into something more entrepreneurial — and making deals.

Continue to STAT Plus to read the full story…

Source link





Related posts

Retinoic acid may improve immune response against melanoma

Newsemia

Healthcare Blockchain Startup Coral Health Announces Health Records App and Upcoming Token Sale (Interview)

Newsemia

Crash and burn: Why three biotechs failed in 2018

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy